Apogee Therapeutics to Announce Phase 2 APEX Trial Results for APG777 on July 7, 2025NoneQuiver News

Apogee Therapeutics will announce Phase 2 APEX trial data for APG777 on July 7, 2025, with a follow-up conference call.Quiver AI SummaryApogee Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology diseases, is set to release Part A 16-week data from its Phase 2 APEX trial of the drug APG777 on July 7, 2025. This announcement will be followed by a conference call and webcas 

SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report Part A 16-week data from the Phase 2 APEX trial of APG777 on Monday, July 7, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.

Webcast Details


Apogee Therapeutics’ live webcast of the Phase 2 APEX Part A results will begin on Monday, July 7

^th

at 8:00 a.m. ET. The live webcast can be accessed via this

link

or the Investors section on the Company’s website at

https://investors.apogeetherapeutics.com/news-events/events

. A replay of the webcast will be available following the call.

About Apogee


Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD, EoE and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the Company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit

https://apogeetherapeutics.com

.

Investor Contact

:

Noel Kurdi

VP, Investor Relations

Apogee Therapeutics, Inc.


[email protected]

Media Contact:


Dan Budwick

1AB


[email protected]